Unicycive Therapeutics (UNCY) Total Non-Current Liabilities (2022 - 2026)
Unicycive Therapeutics posted quarterly Total Non-Current Liabilities of $5.0 million for Q1 2026, down 17.76% year-on-year from $6.1 million in Q1 2025, and up 147.5% on a QoQ basis from $2.0 million in Q4 2025.
Unicycive Therapeutics (UNCY) has 5 years of Total Non-Current Liabilities data on file, last reported at $5.0 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 17.76% year-over-year to $5.0 million; the trailing twelve-month figure through Mar 2026 stood at $5.0 million (down 17.76% YoY), and the FY2025 full-year result was $2.0 million, down 61.84% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $5.0 million, up from $2.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $6.1 million in Q1 2025 and bottomed at -$7.1 million in Q4 2022.
- The 5-year median for Total Non-Current Liabilities is $4.4 million (2023), against an average of $3.6 million.
- The widest annual swing landed in 2023, when Total Non-Current Liabilities soared 168.62%; it then sank 61.84% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at -$7.1 million in 2022, then jumped by 168.62% to $4.9 million in 2023, then climbed by 8.94% to $5.3 million in 2024, then plunged by 61.84% to $2.0 million in 2025, then jumped by 147.5% to $5.0 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $5.0 million (Q1 2026), $2.0 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | 5.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.01 Mn |
| Dec 31, 2025 | 2.02 Mn |
| Sep 30, 2025 | 3.98 Mn |
| Jun 30, 2025 | 3.35 Mn |
| Mar 31, 2025 | 6.09 Mn |
| Dec 31, 2024 | 5.30 Mn |
| Sep 30, 2024 | 4.35 Mn |
| Jun 30, 2024 | 5.23 Mn |
| Mar 31, 2024 | 5.71 Mn |
| Dec 31, 2023 | 4.87 Mn |
| Sep 30, 2023 | 4.48 Mn |
| Jun 30, 2023 | 3.13 Mn |
| Mar 31, 2023 | 3.48 Mn |
| Dec 31, 2022 | -7.09 Mn |